{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T11:43:31Z","timestamp":1771501411821,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T00:00:00Z","timestamp":1569542400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"This study was supported by Genentech, Inc., a Member of the Roche Group"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2019,11]]},"DOI":"10.1007\/s12325-019-01095-1","type":"journal-article","created":{"date-parts":[[2019,9,27]],"date-time":"2019-09-27T10:03:11Z","timestamp":1569578591000},"page":"3079-3095","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":25,"title":["Analysis of Safety, Medical Resource Utilization, and Treatment Costs by Drug Class for Management of Inflammatory Bowel Disease in the United States Based on Insurance Claims Data"],"prefix":"10.1007","volume":"36","author":[{"given":"Gr\u00e1inne H.","family":"Long","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amanda R.","family":"Tatro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Young S.","family":"Oh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sheila R.","family":"Reddy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashwin N.","family":"Ananthakrishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,9,27]]},"reference":[{"key":"1095_CR1","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nrgastro.2015.34","volume":"12","author":"AN Ananthakrishnan","year":"2015","unstructured":"Ananthakrishnan AN. Epidemiology and risk factors for IBD. Nat Rev Gastroenterol Hepatol. 2015;12:205\u201317.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1095_CR2","doi-asserted-by":"publisher","first-page":"1166","DOI":"10.15585\/mmwr.mm6542a3","volume":"65","author":"JM Dahlhamer","year":"2016","unstructured":"Dahlhamer JM, Zammitti EP, Ward BW, et al. Prevalence of inflammatory bowel disease among adults aged\u2009\u2265\u00a018\u00a0years\u2014United States, 2015. Morb Mortal Wkly Rep. 2016;65:1166\u20139.","journal-title":"Morb Mortal Wkly Rep"},{"key":"1095_CR3","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","volume":"12","author":"GG Kaplan","year":"2015","unstructured":"Kaplan GG. The global burden of IBD: from 2015 to 2025. Nat Rev Gastroenterol Hepatol. 2015;12:720\u20137.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1095_CR4","first-page":"S51","volume":"22","author":"F Mehta","year":"2016","unstructured":"Mehta F. Economic implications of inflammatory bowel disease and its management. Am J Manag Care. 2016;22:S51\u201360.","journal-title":"Am J Manag Care"},{"key":"1095_CR5","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1007\/s10620-014-3368-z","volume":"60","author":"DN Floyd","year":"2015","unstructured":"Floyd DN, Langham S, Severac HC, et al. The economic and quality-of-life burden of Crohn\u2019s disease in Europe and the United States, 2000\u20132013: a systematic review. Dig Dis Sci. 2015;60:299\u2013312.","journal-title":"Dig Dis Sci"},{"key":"1095_CR6","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.cgh.2016.09.012","volume":"15","author":"J Limsrivilai","year":"2017","unstructured":"Limsrivilai J, Stidham RW, Govani SM, et al. Factors that predict high health care utilization and costs for patients with inflammatory bowel diseases. Clin Gastroenterol Hepatol. 2017;15:385\u201392.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1095_CR7","unstructured":"Sandborn W, Binion D, Persley K, Atreja A, Kosinski L. AGA Institute guidelines for the identification, assessment and initial medical treatment in Crohn\u2019s disease: clinical decision support tool. American Gastroenterological Association. https:\/\/s3.amazonaws.com\/agaassets\/pdf\/guidelines\/IBDCarePathway.pdf . Accessed 31 Jan 2019."},{"key":"1095_CR8","unstructured":"American Gastroenterological Association. Guidelines for the identification, assessment and initial medical treatment of ulcerative colitis, 2015. https:\/\/s3.amazonaws.com\/agaassets\/pdf\/guidelines\/UlcerativeColitis\/index.html . Accessed 31 Jan 2019."},{"key":"1095_CR9","unstructured":"World Gastroenterology Organisation. World Gastroenterology Organisation global guidelines: inflammatory bowel disease. Updated August 2015. http:\/\/www.worldgastroenterology.org\/guidelines\/global-guidelines\/inflammatory-bowel-disease-ibd\/inflammatory-bowel-disease-ibd-english . Accessed 31 Jan 2019."},{"issue":"11","key":"1095_CR10","first-page":"3","volume":"2017","author":"F Gomollon","year":"2016","unstructured":"Gomollon F, Dignass A, Annese V, et al. 3rd European evidence-based consensus on the diagnosis and management of Crohn\u2019s disease 2016: part 1: diagnosis and medical management. J Crohn\u2019s Colitis. 2016;2017(11):3\u201325.","journal-title":"J Crohn\u2019s Colitis"},{"key":"1095_CR11","doi-asserted-by":"crossref","unstructured":"Harbord M, Eliakim R, Bettenworth D, et al. 3rd European evidence-based consensus on diagnosis and management of ulcerative colitis. Part 2: current management. J Crohn\u2019s Colitis 2017. (Epub prior to print).","DOI":"10.1093\/ecco-jcc\/jjx105"},{"key":"1095_CR12","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/ajg.2008.168","volume":"104","author":"GR Lichtenstein","year":"2009","unstructured":"Lichtenstein GR, Hanauer SB, Sandborn WJ. Management of Crohn\u2019s disease in adults. Am J Gastroenterol. 2009;104:465\u201383.","journal-title":"Am J Gastroenterol"},{"key":"1095_CR13","doi-asserted-by":"publisher","first-page":"571","DOI":"10.1136\/gut.2010.224154","volume":"60","author":"C Mowat","year":"2011","unstructured":"Mowat C, Cole A, Windsor A, et al. Guidelines for the management of inflammatory bowel disease in adults. Gut. 2011;60:571\u2013607.","journal-title":"Gut"},{"key":"1095_CR14","first-page":"72","volume":"113","author":"J Wehkamp","year":"2016","unstructured":"Wehkamp J, Gotz M, Herrlinger K, et al. Inflammatory bowel disease: Crohn\u2019s disease and ulcerative colitis. Dtsch Arztebl Int. 2016;113:72\u201382.","journal-title":"Dtsch Arztebl Int"},{"key":"1095_CR15","unstructured":"Rowe WA. Inflammatory bowel disease treatment and management, 2016."},{"key":"1095_CR16","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1159\/000443135","volume":"34","author":"R Mao","year":"2016","unstructured":"Mao R, Hu PJ. The future of IBD therapy: where are we and where should we go next? Dig Dis. 2016;34:175\u20139.","journal-title":"Dig Dis"},{"key":"1095_CR17","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1038\/ajg.2015.233","volume":"110","author":"L Peyrin-Biroulet","year":"2015","unstructured":"Peyrin-Biroulet L, Sandborn W, Sands BE, et al. Selecting therapeutic targets in inflammatory bowel disease (STRIDE): determining therapeutic goals for treat-to-target. Am J Gastroenterol. 2015;110:1324\u201338.","journal-title":"Am J Gastroenterol"},{"key":"1095_CR18","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1586\/17474124.2014.881715","volume":"8","author":"LP McLean","year":"2014","unstructured":"McLean LP, Cross RK. Adverse events in IBD: to stop or continue immune suppressant and biologic treatment. Expert Rev Gastroenterol Hepatol. 2014;8:223\u201340.","journal-title":"Expert Rev Gastroenterol Hepatol"},{"key":"1095_CR19","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.1038\/ajg.2009.322","volume":"104","author":"J Marehbian","year":"2009","unstructured":"Marehbian J, Arrighi HM, Hass S, et al. Adverse events associated with common therapy regimens for moderate-to-severe Crohn\u2019s disease. Am J Gastroenterol. 2009;104:2524\u201333.","journal-title":"Am J Gastroenterol"},{"key":"1095_CR20","doi-asserted-by":"publisher","first-page":"1655","DOI":"10.1185\/03007995.2015.1065242","volume":"31","author":"ME McAuliffe","year":"2015","unstructured":"McAuliffe ME, Lanes S, Leach T, et al. Occurrence of adverse events among patients with inflammatory bowel disease in the HealthCore Integrated Research Database. Curr Med Res Opin. 2015;31:1655\u201364.","journal-title":"Curr Med Res Opin"},{"key":"1095_CR21","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1002\/ibd.21371","volume":"17","author":"MD Kappelman","year":"2011","unstructured":"Kappelman MD, Porter CQ, Galanko JA, et al. Utilization of healthcare resources by US children and adults with inflammatory bowel disease. Inflamm Bowel Dis. 2011;17:62\u20138.","journal-title":"Inflamm Bowel Dis"},{"key":"1095_CR22","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1136\/gut.2004.041616","volume":"53","author":"A Bassi","year":"2004","unstructured":"Bassi A, Dodd S, Williamson P, et al. Cost of illness of inflammatory bowel disease in the UK: a single centre retrospective study. Gut. 2004;53:1471\u20138.","journal-title":"Gut"},{"key":"1095_CR23","doi-asserted-by":"crossref","first-page":"352","DOI":"10.18553\/jmcp.2008.14.4.352","volume":"14","author":"SJ Bickston","year":"2008","unstructured":"Bickston SJ, Waters HC, Dabbous O, et al. Administrative claims analysis of all-cause annual costs of care and resource utilization by age category for ulcerative colitis patients. J Manag Care Pharm. 2008;14:352\u201362.","journal-title":"J Manag Care Pharm"},{"key":"1095_CR24","doi-asserted-by":"publisher","first-page":"1731","DOI":"10.1053\/j.gastro.2015.08.045","volume":"149","author":"AF Peery","year":"2015","unstructured":"Peery AF, Crockett SD, Barritt AS, et al. Burden of gastrointestinal, liver, and pancreatic diseases in the United States. Gastroenterology. 2015;149:1731\u201341.","journal-title":"Gastroenterology"},{"key":"1095_CR25","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1097\/MIB.0000000000000139","volume":"20","author":"WK van Deen","year":"2014","unstructured":"van Deen WK, van Oijen MG, Myers KD, et al. A nationwide 2010\u20132012 analysis of US health care utilization in inflammatory bowel diseases. Inflamm Bowel Dis. 2014;20:1747\u201353.","journal-title":"Inflamm Bowel Dis"},{"key":"1095_CR26","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1053\/j.gastro.2003.12.003","volume":"126","author":"JD Lewis","year":"2004","unstructured":"Lewis JD, Aberra FN, Lichtenstein GR, et al. Seasonal variation in flares of inflammatory bowel disease. Gastroenterology. 2004;126:665\u201373.","journal-title":"Gastroenterology"},{"key":"1095_CR27","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1002\/pds.4082","volume":"25","author":"X Liu","year":"2016","unstructured":"Liu X, Kubilis P, Bussing R, et al. Development of a refill pattern method to measure polypharmacy in administrative claims databases. Pharmacoepidemiol Drug Saf. 2016;25:1407\u201313.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"1095_CR28","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1097\/MEG.0000000000000891","volume":"29","author":"C Bahler","year":"2017","unstructured":"Bahler C, Schoepfer AM, Vavricka SR, et al. Chronic comorbidities associated with inflammatory bowel disease: prevalence and impact on healthcare costs in Switzerland. Eur J Gastroenterol Hepatol. 2017;29:916\u201325.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"1095_CR29","doi-asserted-by":"publisher","first-page":"7625","DOI":"10.3748\/wjg.v22.i34.7625","volume":"22","author":"AT Abegunde","year":"2016","unstructured":"Abegunde AT, Muhammad BH, Ali T. Preventive health measures in inflammatory bowel disease. World J Gastroenterol. 2016;22:7625\u201344.","journal-title":"World J Gastroenterol"},{"key":"1095_CR30","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/0895-4356(94)90129-5","volume":"47","author":"M Charlson","year":"1994","unstructured":"Charlson M, Szatrowski TP, Peterson J, et al. Validation of a combined comorbidity index. J Clin Epidemiol. 1994;47:1245\u201351.","journal-title":"J Clin Epidemiol"},{"key":"1095_CR31","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/ajg.2010.105","volume":"105","author":"AN Ananthakrishnan","year":"2010","unstructured":"Ananthakrishnan AN, McGinley EL, Binion DG, et al. A novel risk score to stratify severity of Crohn\u2019s disease hospitalizations. Am J Gastroenterol. 2010;105:1799\u2013807.","journal-title":"Am J Gastroenterol"},{"key":"1095_CR32","doi-asserted-by":"publisher","first-page":"1503","DOI":"10.1016\/0895-4356(95)00048-8","volume":"48","author":"P Peduzzi","year":"1995","unstructured":"Peduzzi P, Concato J, Feinstein AR, et al. Importance of events per independent variable in proportional hazards regression analysis. II. Accuracy and precision of regression estimates. J Clin Epidemiol. 1995;48:1503\u201310.","journal-title":"J Clin Epidemiol"},{"key":"1095_CR33","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1016\/0895-4356(95)00510-2","volume":"48","author":"J Concato","year":"1995","unstructured":"Concato J, Peduzzi P, Holford TR, et al. Importance of events per independent variable in proportional hazards analysis. I. Background, goals, and general strategy. J Clin Epidemiol. 1995;48:1495\u2013501.","journal-title":"J Clin Epidemiol"},{"key":"1095_CR34","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1097\/00004836-200110000-00006","volume":"33","author":"AL Buchman","year":"2001","unstructured":"Buchman AL. Side effects of corticosteroid therapy. J Clin Gastroenterol. 2001;33:289\u201394.","journal-title":"J Clin Gastroenterol"},{"key":"1095_CR35","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1053\/j.gastro.2013.11.012","volume":"146","author":"X Roblin","year":"2014","unstructured":"Roblin X, Danese S, Peyrin-Biroulet L. Does anti-TNF therapy costs so many COINs? Gastroenterology. 2014;146:309\u201311.","journal-title":"Gastroenterology"},{"key":"1095_CR36","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.jbspin.2017.01.001","volume":"85","author":"M Sondag","year":"2018","unstructured":"Sondag M, Verhoeven F, Guillot X, et al. \u201cParadoxical\u201d arthralgia occurring under anti-TNFalpha treatment for inflammatory bowel disease. Jt Bone Spine. 2018;85:133\u20134.","journal-title":"Jt Bone Spine"},{"key":"1095_CR37","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.jbspin.2016.02.017","volume":"83","author":"D Wendling","year":"2016","unstructured":"Wendling D. The gut in spondyloarthritis. Jt Bone Spine. 2016;83:401\u20135.","journal-title":"Jt Bone Spine"},{"key":"1095_CR38","doi-asserted-by":"publisher","first-page":"e0145087","DOI":"10.1371\/journal.pone.0145087","volume":"10","author":"S Huoponen","year":"2015","unstructured":"Huoponen S, Blom M. A systematic review of the cost-effectiveness of biologics for the treatment of inflammatory bowel diseases. PLoS ONE. 2015;10:e0145087.","journal-title":"PLoS ONE"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01095-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-019-01095-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-019-01095-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,23]],"date-time":"2021-01-23T15:21:37Z","timestamp":1611415297000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-019-01095-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9,27]]},"references-count":38,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2019,11]]}},"alternative-id":["1095"],"URL":"https:\/\/doi.org\/10.1007\/s12325-019-01095-1","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,9,27]]},"assertion":[{"value":"12 April 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2019","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}